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Abstract: A model for the cardiovascular and circulatory systems has previously been validated in simulated cardiac and 
circulatory disease states. It has also been shown to accurately capture the main hemodynamic trends in porcine models of 
pulmonary embolism and PEEP (positive end-expiratory pressure) titrations at different volemic levels. In this research, 
the existing model and parameter identification process are used to study the effect of different adrenaline doses in healthy 
and critically ill patient populations, and to develop a means of predicting the hemodynamic response to adrenaline. The 
hemodynamic effects on arterial blood pressures and stroke volume (cardiac index) are simulated in the model and 
adrenaline-specific parameters are identified. The dose dependent changes in these parameters are then related to 
adrenaline dose using data from studies published in the literature. These relationships are then used to predict the future, 
patient-specific response to a change in dose or over time periods from 1-12 hours. The results are compared to data from 
3 published adrenaline dosing studies comprising a total of 37 data sets. Absolute percentage errors for the identified 
model are within 10% when re-simulated and compared to clinical data for all cases. All identified parameter trends match 
clinically expected changes. Absolute percentage errors for the predicted hemodynamic responses (N=15) are also within 
10% when re-simulated and compared to clinical data. Clinically accurate prediction of the effect of inotropic circulatory 
support drugs, such as adrenaline, offers significant potential for this type of model-based application. Overall, this work 
represents a further clinical, proof of concept, of the underlying fundamental mathematical model, methods and approach, 
as well as providing a template for using the model in clinical titration of adrenaline in a decision support role in critical 
care. They are thus a further justification in support of upcoming human clinical trials to validate this model. 
Keywords: Cardiovascular system, cardiac model, parameter identification, integral method, adrenaline, epinephrine, 
mathematical model, simulation. 
1. INTRODUCTION 
  Drugs for supporting the cardiovascular system are 
selected to either improve heart rate (chronotropic effects), 
myocardial contractility (inotropic effects), arterial blood 
pressure (vasoconstrictive effects), a reduction in afterload 
(vasodilator effects), or a multiple combination of these 
effects. Many of these drugs also increase electrical 
conduction (dromotropy) within the heart and augment 
relaxation (lusitropy). However, most of these drugs are non 
selective and may also increase or decrease heart rate and 
afterload. These added changes carry the potential risk of 
causing cardiac arrhythmias and increasing myocardial 
ischemia by creating a mismatch between myocardial 
oxygen demand and supply [1]. Additionally, some agents 
also have metabolic effects that increase blood glucose, 
lactate and metabolic rate, and these effects should also be 
taken into account when prescribing such drugs. 
1.1. Drugs in Heart Failure and Cardiogenic Shock 
  The main problem in heart failure and hypotension (as 
caused by an acute heart failure) is a loss of cardiac   
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contractile function with a subsequently reduced organ 
perfusion and hypotension. Drugs used in this case aim to 
improve cardiac output, as it will lead to improved organ 
perfusion and normalization of arterial blood pressure. 
Cardiac function and output can be improved by reducing 
afterload. Similarly, cardiac function and output can also be 
improved by increasing preload by increasing fluid volume 
(for example in hypovolemic and circulatory shock), and 
enhancing contractility of the heart. 
1.2. Drugs in Circulatory Shock 
  This form of hypotensive shock is usually caused by an 
inadequate blood volume as might be caused by hemorrhage. 
It can also be due to a loss of vascular tone caused by 
infection and inflammation, as in septic shock for example. 
The main goal in this case is to improve arterial blood 
pressure and vasoconstrictor drugs are thus typically 
administered, often in the combination with fluid 
administration. 
1.3. Drug Dosing and Infusion Rates 
  Specific drug infusion rates are typically not 
recommended in critically ill patients, mostly due to inter-
patient variations in pharmacokinetics (drug dose - 
concentration relation) and pharmacodynamics (drug 
concentration - effect relation) [2, 3]. Such drugs are thus 150    The Open Medical Informatics Journal, 2010, Volume 4  Chase et al. 
dosed based on an initial dose within a known therapeutic 
range. This dose is then varied (titrated) at the bedside to 
achieve the desired effect on cardiac function, while limiting 
side effects. 
  There are a number of broad guidelines available for the 
appropriate use of these drug therapies in critical care. 
However, sometimes it is not possible to implement these 
algorithms because of patient-specific conditions, resident 
learning curves, and individual physician medication 
preferences [4]. Hence, dosing regimes depend mainly on the 
intuition and experience of the clinical staff and it cannot 
necessarily be guaranteed that the optimal dose for each 
individual patient is chosen or maintained as patient 
condition evolves. 
 Therefore, a clinically validated computerized 
cardiovascular system (CVS) model that provides accurate 
and patient-specific simulations of the cardiovascular and 
circulatory system in response to various doses would offer 
the opportunity for effective use in monitoring and decision 
support roles. A patient-specific model can be used to 
forward simulate the likely response towards a change in 
dose by modifying parameters specific to that drug’s 
physiological affect using either patient-specific data from 
prior changes or generic population estimates from clinical 
studies. More specifically, noting the response to initial 
doses, a patient-specific drug sensitivity could be determined 
to further optimize dosing. Overall, model-based estimation 
of drug effect and its patient sensitivity to enable dose 
optimization would create unique clinical opportunity and 
advantages. 
1.4. Adrenaline (Epinephrine) 
  Adrenaline (European Pharmacopoeia and BAN) or 
Epinephrine (INN) functions as a hormone in the 
bloodstream and as a neurotransmitter when released across 
a neuronal synapse. Adrenaline is released by the adrenal 
medulla upon activation of preganglionic sympathetic nerves 
innervating this tissue. This activation occurs during times of 
stress, such as during exercise, heart failure, hemorrhage, 
excitement or pain. Circulating adrenaline causes [5]: 
•  Increased heart rate and inotropy (_1-adrenoceptor 
mediated) 
•  Vasoconstriction in most systemic arteries and veins 
(postjunctional  _1- and  _2 -adrenoceptors mediated) 
•  Vasodilation in muscle and liver vasculatures at low 
concentrations ( _2 -adrenoceptor mediated) 
•  Vasoconstriction at high concentrations ( _1-
adrenoceptor mediated) 
1.4.1. Adrenaline Usage in Critically Ill Patients 
  An observational study, which enrolled 84 patients in an 
ICU between February and March 2005, showed that 
between 35% and 45% of patients were treated with 
inotropes [6]. Adrenaline is used in patients who are in 
cardiac arrest or who require inotropic or vasopressor 
support. Adrenaline may additionally be used in cases of 
anaphylaxis associated with hemodynamic instability or 
respiratory distress [1, 7]. Furthermore, it improves myocar-
dial and cerebral hemodynamics during cardiopulmonary 
resuscitation (CPR). 
1.5. Goals for this Research 
  The goals for this research are twofold. The first aim is to 
test the CVS model in drug therapy scenarios and by doing 
so to provide a basis for future clinical trials. Ultimately, the 
goal is to use the CVS model and methods developed to 
predict the patient’s response towards different drugs and 
doses over time to individualize and customize this aspect of 
patient care. 
  Pharmaceuticals represent 4% to 7% of the yearly 
operating expense of most hospitals [8] and in ICUs this 
value ranges from 32.6% to 41.5% of a hospital’s total drug 
costs [9]. Hence, there is a growing financial demand for 
optimizing the amount of drugs prescribed and avoiding 
unnecessary prescriptions. Use of this CVS model, or 
similar, could help reduce these costs by allowing the 
appropriate patient-specific dose to be found more 
efficiently, as well as by identifying patient-specific 
conditions when dosing is necessary (or unnecessary). 
  It should be pointed out that this CVS model so far has 
only been clinically validated using data from porcine 
experiments [10-14] within a very controlled environment. 
In these cases, desired effects are induced purposefully and 
usually not treated. However, data obtained from clinical 
trials on critically ill patients, adds the challenge of a 
multivariate environment, where a variety of therapeutic 
treatments are performed and drugs are administered 
combined with different ventilatory support options and fluid 
administration. Therefore, it is important to know the effect 
each individual treatment option is likely to have and how 
the parameters in the CVS model may need to be adjusted to 
correctly represent these changes. 
  This study uses human clinical data from 3 adrenaline 
(epinephrine) dose response studies found in the clinical 
literature [15-17]. Adrenaline is a low cost drug, so in this 
case the motivation for optimizing the dose is not purely on 
the specific costs of this drug, although it demonstrates the 
concept and could be applied to other drugs. More 
importantly, better dosing of adrenaline can reduce general 
health care costs [18] and may avoid the use of other more 
expensive drugs like dobutamine [19]. The adrenaline 
studies investigated in this paper present hemodynamic data, 
such as arterial pressures and the cardiac index, at the level 
of detail needed for the model identification process, and 
over periods from one to several hours. Thus, this research 
demonstrates the ability of the CVS model and methods to 
develop clinical protocols based on data from human trials 
and studies. 
  The goal is to be able to identify the underlying patient-
specific parameters that allow the representation of the 
patient’s hemodynamic status and adrenaline dose response 
within this CVS model. Note that the model is not in a 
unified form that is directly applicable in the general case. 
Rather, it is treated as a broad structure, which is adapted to 
each individual situation and provides a starting point for 
aggregating a diverse range of data sets into a more 
physiological and simpler form for clinicians. More 
specifically, the CVS model is identified for each data set 
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of that patient, expressed in the different parameter values 
and trends over time. These patient-specific parameter values 
and trends are then used to develop a general relationship to 
predict a patient’s response over time to a change in 
adrenaline dose. Hence, any correlations between 
hemodynamic measurements for example interdependencies 
between time histories of the arterial pressure are implicitly 
accounted for in the model. These predictions are then 
compared to the clinical data from these studies [15-17]. 
Results are presented in form of absolute percentage errors 
between predicted and clinically observed data. 
2. METHODS 
2.1. CVS Model 
  The CVS model is a simple, yet clinically validated 
model for the heart and circulation [10-13, 20-22]. This 
model comprises a series of connected pressure-volume 
chambers with greater detail for the active ventricular 
portions of the heart and their interaction. More specifically, 
the left/right ventricle, aorta, pulmonary artery/vein, vena 
cava are captured as explicit physiological regions with 
independent fundamental circulatory (PV) dynamics. Fig. (1) 
gives an overview of the CVS model and a more detailed 
description of the model can be found in [11-13]. 
2.2. Integral-Based Parameter Identification 
  The parameter identification method used in this research 
has previously been shown to rapidly and accurately identify 
most of the parameter set in the presence of significant 
measurement noise [10, 23]. As the identification process 
has been extensively described [11-13], only a brief 
summary of the individual steps is provided here. 
2.3. Summary of the Identification Process 
 Fig.  (2) gives an overview of the identification process 
based on previous work [10-12,23]. The following steps are 
performed: 
1.  Obtain clinical measurements and signals 
2.  Use volume calculations to estimate the initial 
volume conditions for the CVS model (see [11]) 
3.  Use initial set of parameters to obtain first simulation 
output (see [10-12]) 
4.  Scale simulation output signals (Ppa,  P ao , Vlv , Vrv ) to 
match the clinical data (see [10-12]) 
5.  Identify the patient-specific parameters for the scaled 
signals using the integral-based methods based on 
[23] 
6.  Re-scale the simulation output signals to better match 
the clinical data 
7.  Repeat steps 4 to 6, and stop the iterative process 
when a set error tolerance is reached 
2.4. Experimental Protocols 
  Three clinical studies reported in the literature were used 
in this research [15-17]. Results from each are employed 
here to identify the CVS model. Hence, the clinical data is 
thus not the work of the authors and only the available 
published results are used here. 
2.4.1. Study 1: Effects of Age on Cardiovascular Responses 
to Adrenaline in Man 
  In this study [15], Adrenaline was administered to 14 
young normotensive subjects (age 21-40 years, mean 30± 2 
years; 8 male, 6 female) and 18 older normotensive subjects 
(age 50-73 years, mean 60± 2 years; 6 male, 12 female). All 
subjects had weight within 20% of the ideal body weight. 
They all had normal history, physical examination and 
biochemistry. The subjects were instructed to refrain from 
caffeine and alcohol 24 hours prior to each study morning 
and they did not take any other medication for the duration 
of the study. The study was approved by the Human Ethics 
Committee of the University of Ottawa and written informed 
consent was obtained. 
  Arterial blood pressure (ABP) was measured using a 
blood pressure cuff applied to the arm that was not used for 
the infusion. Blood pressure was recorded using a Roche 
Arteriosonde (Roche Medical Electronics Inc., Cranbury, NJ, 
USA). ECG electrodes were applied to measure heart rate 
(HR) by a Tektronic 414 monitor (Tektronic Inc., Beaverton, 
OR, USA). On the study morning, following a rest period of 
at least 60 minutes, adrenaline was started at 20 ng/kg/min 
and increased to 40, 80, 120 and 160 ng/kg/min or until the 
heart rate had increased by 20-25 beats/min or the diastolic 
blood pressure decreased by 15 mmHg. Each dose was 
infused for 8 mins. Heart rate and blood pressure were 
measured every 2 mins for 10 minute periods prior to the 
start of an infusion and twice during the last 2-3 mins at each 
infusion rate. Mean and standard deviation are used for 
analysis. 
 Table  1 summarizes the data obtained from this study for 
the different adrenaline doses and populations (young/older 
and male/female). The following measurements are used for 
the parameter identification process: 
•  heart rate (HR) 
•  systolic and diastolic arterial pressures (SAP, DAP) 
•  left ventricular end-systolic and end-diastolic volume 
indexes (LVESVI, LVEDVI) 
•  left ventricular stroke volume (LVSV, as calculated 
from LVEDVI and LVESVI) 
  Overall, this study provides 24 unique data sets that may 
be used. 
2.4.2. Study 2: The Metabolic and Renal Effects of 
Adrenaline and Milrinone in Patients with Myocardial 
Dysfunction After Coronary Artery Bypass Grafting 
  In this study [16], 251 patients were screened over 18 
months for low cardiac output (CO) upon ICU admission 
after coronary artery bypass grafting (CABG) surgery. 
Approval of the local Ethics Committee and preoperative 
written consent was obtained. Patients having a cardiac 
index (CI) of less than 2.2 l / min / m
2  upon ICU admission 
(despite adequate arterial and filling pressures) were 
randomly assigned to 14-hour treatment with adrenaline 
(n=7) or milrinone (n=11) to achieve a CI of greater then 3 
l / min / m
2 . 
 152    The Open Medical Informatics Journal, 2010, Volume 4  Chase et al. 
 
Fig. (1). Overview of the CVS model used in this research.  
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  Drugs were given by continuous infusion without a 
bolus. Treatment in the ICU and the care provided to the 
patients was at the discretion of the clinical staff in charge. 
With the exception of the hemodynamic goals given above 
and the prohibition of using diuretics or hydroxyethylstarch 
preparations during the treatment duration, no specific 
therapeutic instructions were given. 
  All patients had a radial arterial line, a central venous 
catheter and a pulmonary artery catheter for continuous 
measurement of mixed venous oxygen saturation (SvO2) and 
CI (Vigilance, Edwards Lifesciences LLC, Irvine, CA, 
USA). Hemodynamics were recorded every two hours for a 
14 hour treatment period after ICU admission. The 
hemodynamic variables recorded include: mean arterial 
pressure (MAP), central venous pressure (CVP), mean 
pulmonary artery pressure (MPAP), HR and CI. The 
following subset of available measurement data are used for 
the parameter identification process: 
•  heart rate (HR) 
•  mean arterial and mean pulmonary artery pressures 
(MAP, MPAP) 
•  cardiac index (CI) 
•  central venous pressure (CVP) 
  Overall, this data from [16] provided 8 data sets for use. 
2.4.3. Study 3: Comparison of Norepinephrine and 
Dobutamine to Epinephrine for Hemodynamics, Lactate 
Metabolism, and Gastric Tonometric Variables in Septic 
Shock: A Prospective, Randomized Study 
  This study [17] included 30 patients with hyperdynamic 
septic shock and was approved by the local Ethics 
Committee and written informed consent was obtained from 
the patient’s closest relative. To be included in the study 
after volume resuscitation and treatment with dopamine up 
to a dose of 20μg/kg/min, the patients had to have the 
following baseline condition: 
• MAP  60mmHg 
•  signs of altered perfusion (oliguria, <30ml/hr) or 
increased lactate level (>2.5mml/l) 
• CI  > 3.5l / min / m
2  
  Heart rate was monitored continuously and the routine 
clinical monitoring included a thermodilution pulmonary 
artery catheter, with continuous monitoring of mixed venous 
oxygen saturation ( SvO2) and a radial and femoral artery 
catheter. Measurements of MAP, CVP, MPAP were taken 
and CO was measured by thermodilution. Each patient 
received either epinephrine or norepinephrine + dobutamine. 
Epinephrine infusions were started at 0.3 μg/kg/min. The 
infusion rate was titrated on MAP at 5-min intervals to 
obtain a MAP > 80mmHg, with a stable or increased CI. 
 Table  2 summarizes the adrenaline titration given. The 
following measurements are used for the parameter 
identification process: 
•  heart rate (HR) 
•  mean arterial and mean pulmonary artery pressures 
(MAP, MPAP) 
•  cardiac index (CI) 
•  central venous pressure (CVP) 
  Overall, 5 data sets were available for use in this study. 
2.5. Estimations and Prediction Process 
  Depending on the data available for each study, different 
assumptions about the rest of the data had to be made. 
Generally, the prediction process uses some measure of past 
 
Fig. (2). Flowchart of the identification process, performed to calculate the optimal set of CVS model parameters that best represent the 
clinical data.  
Choose initial set of parameters
Simulation
Scale output signals to 
measured data
Identify patient specific 
parameters
Simulation output acceptable?
End
Start
Simulation
Measured data
yes
no154    The Open Medical Informatics Journal, 2010, Volume 4  Chase et al. 
information on how the patient responded towards a change 
in adrenaline dose to predict how the patient is likely to 
respond towards a future change in dose. Hence, the 
adrenaline responses from other patients are not required to 
make a prediction, so population model evaluation methods 
like cross-validation, are not appropriate in this case. 
Table  1.  Adrenaline Doses and Participants Separated into 
Young and Older and Young Male,  Young Female 
and Older Male and Female, Respectively 
 
 Study 1: Adrenaline Doses and Populations 
Adrenaline Dose (ng/kg/min)  Number of Participants 
Young (Y) 
 Baseline  14 
 20  14 
 40  14 
 80  14 
 120  13 
 160  13 
 Older (O) 
 Baseline  18 
 20  18 
 40  18 
 80  18 
 120  16 
 160  10 
 Young Male (YM) 
 Baseline  8 
 40  8 
 Max (150)  8 
 Young Female (YF) 
 Baseline  6 
 40  6 
 Max (160)  6 
 Older Male (OM) 
 Baseline  6 
 40  6 
 Max (133)  6 
Older Female (OF) 
 Baseline  12 
 40  12 
 Max (140)  12 
 
  The set of parameters chosen to primarily govern 
prediction are highly dependent on the patient condition, the 
time periods involved and the therapy chosen. The technique 
presented in this paper is to first identify the main parameters 
that physiologically should change based on previous data 
and knowledge in the literature. The next step is to predict 
forward in time on data that has not been fitted to. If 
predictions are within a reasonable error, the parameters can 
be said to adequately describe the impact of the therapy 
under consideration. If not the parameter set or the model 
needs to be expanded to allow more dynamics. Clinical trials 
are required to put precise magnitudes on how accurate a 
prediction needs to be to provide a measurable patient 
outcome. 
Table 2.  Time Course and Drug Titration for Study 3 
 
 Study 3: Adrenaline Titration and Course of Time 
   Baseline   h1   h6   h12   h24 
Drug titration 
(μg/kg/min) 
 0   0.45±0.09   0.52±0.07   0.48±0.08  0.36±0.08 
 
  Depending on the data available, the prediction process is 
adjusted for each of the 3 studies as described below. The 
error metrics chosen are always the median and a range 
estimate. The reason for this choice is that clinical errors and 
data are very rarely normally distributed [24] so that metrics 
based on the mean are not as robust. Hence a range metric 
(IQR) is chosen since it is independent of the distribution. 
2.5.1. Adrenaline-Specific Parameters 
  As discussed before, the effects of adrenaline can be 
summarized as an increase in HR and contractility, 
vasoconstriction in most systemic arteries and veins and an 
increase in the central blood volume. These effects in turn 
lead to an increase in SV and systemic arterial pressure 
(SAP). Diastolic arterial pressure (DAP) is decreasing, and 
thus a relatively constant mean arterial pressure (MAP) 
results, but with a largely increased pulse pressure (PP). 
Consequently, from these physiologically expected effects 
the model parameters (see Fig. 1) that should be most 
influenced by adrenaline, are: 
•  left and right ventricular end-systolic elastances 
( Eeslvf ,  Eesrvf ); also representing the contractility 
•  arterial and pulmonary elastances Eao  and  Epa ; as 
affected by the change in pulse pressure 
•  systemic arterial resistance  Rsys ; as affected by 
vasoconstriction 
• systemic  elastance  Esys  (1/compliance); affected by 
increases in Vsys  
  As the most pronounced changes are expected in  Eeslvf , 
Eesrvf ,  Eao  and  Epa , these parameters are termed the 
adrenaline-specific parameters. Changes in these parameter 
values are therefore used for predicting the future response 
towards a change in dose of adrenaline or over time. 
However, for studies 2 and 3 [16,17], changes in Rsys  and 
Esys  were also included in the prediction rules. This 
difference can be explained by the overall much longer time 
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the patients is more likely to have changed, for example due 
to vasoconstriction and/or a change in blood volume over 
that time period. 
2.5.2. Study 1 
  This study provided the best data for the identification 
process, with very detailed data reported over a variety of 
subjects and conditions. As this study was a planned 
interventional clinical trial study, it took place in a very 
controlled environment and adrenaline was administered into 
each participant following a strict protocol. It is thus safe to 
assume it was administered in exactly the same way, with 
the same dose, and over the same time, for each participant. 
  Hence, this part of the study presented concentrates on 
demonstrating the ability of the CVS model to simulate the 
different effects of adrenaline, identifying general 
relationships between adrenaline dose and model parameters, 
and testing the model’s shorter term predictive ability in 
response to changes in dose. 
  All 16 individual data sets obtained from the study (6 
data sets per dose for Y and O group plus one additional set 
for the YM, YF and OM, OF groups at baseline, see also 
Table 1) were identified using the methods described in [10-
12]. The changes in the adrenaline-specific parameters 
( Eeslvf ,  Eesrvf ,  Eao  and  Epa ) in the Y group were observed 
and a linear fit was obtained for the 5 dose changes from 
baseline to 160 ng/kg/min. This trend is used for prediction. 
  Predictions are performed for the (independent) O group 
and then the (independent) YM, YF, OM andOF data sets. 
The first prediction in each data set uses the baseline 
parameters identified for each of these groups (O, OM, OF, 
YM, YF), as it is necessary to have a baseline solution vector 
of model parameters to begin. The adrenaline-specific 
parameters ( Eeslvf ,  Eesrvf ,  Eao  and Epa ) are then modified to 
account for a change in dose from the baseline, using the 
linear prediction rule obtained from the linear fit in the Y 
group. With these modified adrenaline-specific parameters, 
the model is run and the predicted hemodynamic output 
signals for SAP, DAP, MAP, LVEDVI, LVESVI and SV are 
compared to the clinical data from [15]. Median absolute 
percentage errors and the inter-quartile range (IQR) are 
calculated. 
  A second type of prediction is also performed. In this 
case, the previous model parameter value vector identified 
from the previous change in dose is used, rather than those 
from the baseline parameter vector. This effectively shortens 
the interval or dose over which the adrenaline-specific 
parameter changes are employed. The adrenaline-specific 
parameters ( Eeslvf ,  Eesrvf ,  Eao  and  Epa ) are then modified 
based on the linear prediction rule as before and the model is 
then forward simulated again to obtain a prediction of the 
hemodynamic outcome to the change in dose. Finally, the 
resulting predicted output signals for SAP, DAP, MAP, 
LVEDVI, LVESVI and SV are compared to the clinical data. 
Median absolute percentage errors and the inter-quartile 
range (IQR) are calculated. 
  In this study, the pulmonary artery pressure is not given 
and has to be estimated. The pulmonary artery pressure is 
estimated as a constant pressure over all dosages and 
participant groups with a systolic value of 25 mmHg and a 
diastolic value of 12 mmHg. Note, that this estimation is 
physiologically incorrect, as the pulmonary artery pressure is 
expected to change with different doses of adrenaline. 
However, by keeping this pressure fixed for all 
identifications, it can be guaranteed that only a constant error 
is added to the identification process. This error can be much 
better managed if it is similar for all identified segments. 
Naturally, information about the pulmonary circulation is 
lost and the value of  Epa  will also not necessarily represent a 
true value in this case. 
2.5.3. Studies 2 and 3 
  These 2 studies are used as further tests. In particular, 
they test the potential to correctly identify patient-specific 
parameters in the absence of diastolic and systolic pressure 
measurements, given only the mean arterial pressures MAP 
and MPAP. In addition, these 2 studies do not provide end-
systolic or end-diastolic volumes, relying instead on the 
cardiac index. Finally, the data in these studies covers much 
longer time periods extending the prediction range. 
  As noted, these 2 studies measure a very minimal amount 
of data. Hence, several assumptions have to be made to use 
the data in this study: 
•  SV is calculated based on HR and CI with an 
assumed  BSA = 2m
2  in all cases 
•  ESV is assumed as SV+10ml 
•  EDV is calculated as ESV+SV 
•  left and right ventricular volumes are assumed to be 
the same 
•  systolic and diastolic pressures are estimated based on 
Fig. (3) as obtained from [5] 
 
Fig. (3). Change in diastolic and systolic blood pressure in 
comparison to a relatively constant mean arterial pressure with 
administration of epinephrine (adrenaline) over time, as obtained 
from [5]. 
  In these 2 studies, there is only a limited amount of data 
available. In comparison to study 1, this data is very 
inhomogeneous and was not obtained in a controlled study.  
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Instead, it was taken observationally over time periods of 14 
and 24 hours, respectively. Therefore, these data sets were 
not intended to truly predict the patient’s response towards a 
change in dose in adrenaline, or over the course of time. 
  The goal in these data sets is to show the accuracy of the 
identification process by testing if an overall rule can be 
found that shows a consistent way of identifying the main 
adrenaline-specific parameters. If such a simple, linear rule 
can be found, using all or most of the data points available, 
then this rule would show that the parameters evolved in a 
consistent manner. This rule could then be used to predict 
the patient’s response for a specific point in time. If 
successful, it would demonstrate the approach of using drug-
specific rules and parameter changes to enhance 
identification and prediction. 
  For study 2, prediction rules are obtained from the 
absolute percentage changes in the model parameter values 
from one point in time to the next, except for the change 
from baseline to t2. This percentage difference is not 
included because this change is expected to be much higher, 
as the effect of adrenaline is expected to be more pronounced 
compared to the other time points where the adrenaline dose 
is kept at a more constant level. A total of 6 predictions are 
performed for study 2 from t4 to t14, using the previous 
solution as baseline solution in each case. For example, for 
predicting the response at t4, the parameters from t2 are used 
plus the re-calculated adrenaline-specific parameters using 
the overall population rule, as described before. In contrast 
to study 1, where the adrenaline-specific parameters are 
Eeslvf ,  Eesrvf ,  Eao  and  Epa , for this data set it was necessary 
to also re-calculate the systemic and pulmonary arterial 
resistances  Rsys  and  Rpul  and the systemic elastance  Esys . 
These 3 additional parameters changed significantly during 
the time course of the study and were thus included in the 
overall population rule. 
  Similarly to study 2, the prediction rules for study 3 are 
obtained from the absolute percentage changes in the 
parameters from one point in time to the next. However, here 
only the change from h1 to h6 is used. The baseline change 
was excluded for the same reason as in study 2. For similar 
reasons the change to h24 was excluded, as this change 
covers a long time period (12 hours). In addition, while the 
doses for h1, h6 and h12 are similar, there is a much lower 
dose at h24. Hence, only 1 prediction is performed for study 
3 and this is the prediction for h12, using the data obtained 
from h1 and h6. 
  This prediction from study 3 serves as another test of the 
CVS model and identification process. The goal is to show 
that all parameters are identified in such a consistent way 
that h1-h6 adrenaline-parameter specific rules can be found 
to predict h12. The adrenaline-specific parameters  Eeslvf , 
Eesrvf ,  Eao  and  Epa  used with study 1 are augmented for 
study 3 to include  Rsys , which changed considerably during 
the long time course of this study. Fig. (4) shows the 
prediction rules obtained for studies 2 (solid line) and 3 
(dashed line) for Eeslvf  and Eesrvf  over a time period of 1 to 
24 hours, where the similarity over disparate studies 
indicates a consistent underlying physiological behaviour. 
 
Fig. (4). Linear prediction rules for  Eeslvf  (upper panel) and  Eesrvf  (lower panel) for studies 2 (Heringlake et al., solid line) and 3 (Levy et 
al., dashed line).  
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3. RESULTS 
3.1. Study 1 
3.1.1. Identification Results 
 Fig.  (5) shows in the upper panel (solid line) the mean 
systolic arterial pressure (SAP) over all 16 segments as given 
in [15]. These 16 segments are the 6 measurements for the 
young and older groups at baseline, 20, 40, 80, 120 and 160 
ng/kg/min adrenaline (segments 1-6 young, 7-12 older), plus 
4 measurements, which are obtained by separating the young 
and older groups for male and female, respectively. The 
circles are the simulated CVS model outputs obtained when 
the CVS model is re-run with the identified patient-specific 
parameters. 
  The middle panel shows as a solid line the mean arterial 
pressure (MAP) as available in [15] for all 16 segments. The 
circles depict the CVS model output data when re-run using 
patient-specific parameters. The lower panel shows the same 
results for the diastolic arterial pressure (DAP). 
 Fig.  (6) shows in the upper panel the left ventricular end-
diastolic index (LVEDVI) as given in [15], whereas the 
lower panel shows the left ventricular end-systolic index 
(LVESVI). A total of 16 identifications were performed, 
 
Fig. (5). Study 1: Clinical mean systolic (SAP), diastolic (DAP) and mean (MAP) arterial pressure as obtained from [15] vs simulated 
pressures. Solid lines represent the clinical data and circles represent the CVS model simulation output using identified patient-specific 
parameters.  
 
Fig. (6). Study 1: Clinical mean left ventricular end-diastolic (LVEDVI) and end-systolic (LVESVI) volume index as obtained from [15] vs 
simulated volume indexes. Solid lines represent the clinical data and circles represent the CVS model simulation output using identified 
patient-specific parameters.  
2 4 6 8 10 12 14 16
100
150
S
A
P
 
i
n
 
m
m
H
g
2 4 6 8 10 12 14 16
70
80
90
100
M
A
P
 
i
n
 
m
m
H
g
2 4 6 8 10 12 14 16
60
80
# identifications
D
A
P
 
i
n
 
m
m
H
g
2 4 6 8 10 12 14 16
60
70
80
90
L
V
E
D
V
I
 
i
n
 
m
l
/
m
2
2 4 6 8 10 12 14 16
5
10
15
20
25
# identifications
L
V
E
S
V
I
 
i
n
 
m
l
/
m
2158    The Open Medical Informatics Journal, 2010, Volume 4  Chase et al. 
with 6 identifications each in the young and older group plus 
another 4 identifications separated for male and female, as 
described previously. The circles represent the CVS model 
output signals. 
 Table  3 gives an overview of how well the CVS model 
output data matches the data given in [15]. The absolute 
median percentage error is given as well as the inter-quartile 
range (IQR). These two values are calculated over all 16 
identified segments. 
Table 3.  Study 1, Identification: Median Error and IQR in % 
for Measured and Simulated Pressures and Volumes 
Over All 16 Identified Segments 
 
 Absolute Percentage Error for Measured and  
Simulated Pressures and Volumes 
   SAP 
 (%) 
 DAP 
 (%) 
 MAP 
 (%) 
 LVEDVI 
 (%) 
 LVESVI 
 (%) 
 SV 
 (%) 
 Median   3.27   1.70   1.94   2.15   6.79   3.37 
 IQR   3.06   1.77   2.44   1.76   7.22   1.05 
SAP = systolic arterial pressure, DAP = diastolic arterial pressure, MAP = mean 
arterial pressure, LVEDVI = left ventricular end-diastolic volume index, LVESVI = 
left ventricular end-systolic volume index. 
 
3.1.2. Prediction Results 
 Table  4 gives the median absolute percentage errors and 
IQR for prediction 1 in study 1. This prediction uses a 
population-specific rule obtained only from the young 
population to describe the changes in the main adrenaline-
specific model parameters caused by an increase in the 
adrenaline dose from baseline and 20 ng/min/kg to 160 
ng/min/kg. Note that the baseline solution vector was used as 
initial solution for each time step and only the adrenaline-
specific parameters were updated according to the 
population-specific rule. 
Table 4.  Study 1, Prediction 1: Median Error and IQR in % 
for Measured and Predicted Pressures and Volumes 
Over All 13 Predicted Episodes when the Baseline 
Parameter Vector is Used as Initial Solution 
 
 Absolute Percentage Error for Measured and  
Predicted Pressures and Volumes 
   SAP 
 (%) 
 DAP 
 (%) 
 MAP 
 (%) 
 LVEDVI 
 (%) 
 LVESVI 
 (%) 
 SV 
 (%) 
 Median   11.03   11.47   10.21   3.49   0.48   7.66 
 IQR   5.76   13.81   9.58   4.88   11.35   4.45 
SAP = systolic arterial pressure, DAP = diastolic arterial pressure, MAP = mean 
arterial pressure, LVEDVI = left ventricular end-diastolic volume index, LVESVI = 
left ventricular end-systolic volume index. 
 
 Table  5 gives the median absolute percentage errors and 
IQR for prediction 2 in study 1. This second prediction uses 
the same population-specific rules as were used in prediction 
1. However, in contrast to prediction 1, the previous solution 
is used as initial solution, rather than the baseline solution. 
Thus, for example, for predicting and calculating the 
parameters for a dose of 120 ng/min/kg, the identified 
parameters for a dose of 80 ng/min/kg are used. 
Table 5.  Study 1, Prediction 2: Median Error and IQR in % 
for Measured and Predicted Pressures and Volumes 
Over All 13 Predicted Episodes when the Previous 
Parameter Vector is Used as Initial Solution 
 
 Absolute Percentage Error for Measured and  
Predicted Pressures and Volumes 
   SAP 
 (%) 
 DAP 
 (%) 
 MAP 
 (%) 
 LVEDVI 
 (%) 
 LVESVI 
 (%) 
 SV 
 (%) 
 median   2.60   6.72   4.66   2.99   8.78   6.62 
 IQR   3.33   5.59   4.29   2.93   12.00   4.76 
SAP = systolic arterial pressure, DAP = diastolic arterial pressure, MAP = mean 
arterial pressure, LVEDVI = left ventricular end-diastolic volume index, LVESVI = 
left ventricular end-systolic volume index. 
 
3.2. Study 2 
3.2.1. Identification Results 
 Fig.  (7) shows in the upper panel (solid line) the mean 
arterial pressure (MAP) over 14 hours as given in [16]. The 
circles represent the CVS model outputs obtained when the 
CVS model is re-run with the identified patient-specific 
parameters. The middle panel shows as a solid line the mean 
pulmonary artery pressure (MPAP) as obtained from [16] 
over the 14 hour study period. The circles depict the CVS 
model output data when re-run using the identified 
parameters. The lower panel shows the same results for the 
cardiac index (CI). 
 Table  6 gives an overview of how well the CVS model 
output data matches the data given in [16] in terms of 
median and inter-quartile range (IQR). These values are 
provided over all 8 identified segments for the total 14-hour 
study period. 
3.2.2. Prediction Results 
 Table  7 gives the median absolute percentage errors and 
IQR for predicting the hemodynamic responses in MAP, 
MPAP and CI based on the time in the study. Note, that the 
rules for the adrenaline-specific parameters were obtained 
from the middle time segments at 2 to 12 hours. The 
hemodynamic responses are predicted for 6 different time 
segments at 4, 6, 8, 10, 12 and 14 hours. The previous 
parameter solution vector was used as the initial solution for 
each predicted segment. 
3.3. Study 3 
3.3.1. Identification Results 
 Fig.  (8) shows in the upper panel (solid line) the mean 
arterial pressure (MAP) over 24 hours as given in [17]. The 
circles represent the simulated CVS model outputs obtained 
when the CVS model is re-run with the identified patient-
specific parameters. The middle panel shows as a solid line 
the mean pulmonary artery pressure (MPAP) as obtained 
from [17] over the 24 hour study period. The circles 
represent the CVS model output data when re-run using the 
identified parameters. The lower panel shows the same 
results for the cardiac index (CI). It should be noted that the 
last prediction for MPAP in Fig. (7) is significantly less 
accurate than all other predictions. This effect could be 
random but the variation in MPAP is not sufficient enough to Model-Based Prediction of the Patient-Specific Response to Adrenaline  The Open Medical Informatics Journal, 2010, Volume 4    159 
properly assess this result, since it is still only 2 mmHg in 
error, which is clinically small. Further results over a longer 
time period that have bigger fluctuations in MPAP would be 
required to fully understand whether or not this effect is a 
potential modeling error that needs to be addressed. 
Table 6.  Study 2, Identification: Median Error and IQR in % 
for Measured and Simulated Pressures and Volumes 
Over All 8 Identified Segments 
 
 Absolute Percentage Error for Measured and  
Simulated Arterial Pressures and CI 
   MAP 
 (%) 
 MPAP 
 (%) 
 CI 
 (%) 
 median   0.99   3.05   1.57 
 IQR   0.94   1.67   0.45 
MAP = mean arterial pressure, MPAP = mean pulmonary artery pressure, CI = cardiac 
index. 
 
Table 7.  Study 2, Prediction: Median Error and IQR in % 
for Measured and Predicted Pressures and Volumes 
Over All 6 Predicted Segments when the Previous 
Solution Vector is Used as Initial Parameter Vector 
 
Absolute Percentage Error for Measured and  
Predicted Arterial Pressures and CI 
   MAP 
 (%) 
 MPAP 
 (%) 
 CI 
 (%) 
 median   4.26   5.51   4.50 
 IQR   3.73   4.46   2.95 
MAP = mean arterial pressure, MPAP = mean pulmonary artery pressure, CI = cardiac 
index. 
 Table  8 gives an overview of how well the CVS model 
output data matches the data in [17]. The median absolute 
percentage error is shown, as well as the inter-quartile range 
(IQR). These two values are calculated over all 5 identified 
segments for the total study period of 24 hours. 
3.3.2. Prediction Results 
 Table  9 gives the median absolute percentage errors and 
IQR for predicting the hemodynamic responses in MAP, 
MPAP and CI based on the time in the study. The rules for 
the adrenaline-specific parameters were obtained from the 
time segments h1 and h6 to predict a single response at h12. 
The parameter solution vector at h6 was used as initial 
solution for the prediction of h12. 
4. DISCUSSION 
  For all 3 studies, the model simulation output signals 
match the clinical data very well, as can be seen in Figs. (5, 
6) for study 1, and Figs. (7,  8) for studies 2 and 3, 
respectively. The absolute percentage errors (median and 
IQR) between simulated and clinical data for arterial 
pressures (SAP, DAP and/or MAP), ventricle volume 
indexes (LVEDVI and LVESVI), stroke volume (SV) and/or 
cardiac index (CI) for all 3 studies are given in Tables 3-8. It 
can clearly be seen, that all median identification percentage 
errors are less than 9%. An error of 10% is a reasonable 
estimate of measurement error in hemodynamic monitoring. 
For example, in continuous cardiac output monitoring, the 
percentage repeatability coefficient can vary from 6.4-26% 
and no monitor can have limits of agreement closer than + 
0.5 L/min [25]. Given that a normal cardiac output is 
5L/min, a 10% error is a rough guideline in this case. MAP 
is known to be sensitive to patient position depending on the 
transducer placement with errors that can vary from 2.9-1.9 
mmHg [26]. Given that normal MAP is 80 mmHg these 
 
Fig. (7). Study 2: Clinical mean arterial (MAP), mean pulmonary artery (MPAP) pressure and cardiac index (CI) as obtained from [16] vs 
simulated pressures and CI. Solid lines represent the clinical data and circles represent the CVS model simulation output using identified 
patient-specific parameters.  
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errors correspond to a percentage variation of between 3.6 
and 18.6%. There can also be distortions in the arterial 
pressure waveform which can significantly affect 
calculations in SAP and DAP [27]. Thus 10% is chosen to be 
a reasonably conservative threshold where the model can be 
considered to adequately capture and predict the measured 
data. This value is within or near expected measurement 
errors. 
  These results show the good overall accuracy of the 
identification method and parameters found. It also shows 
the model’s ability to capture these dynamics in 
physiologically expected ways, as well as the assumptions 
and estimations made. In particular, such generally good 
identifications are not likely possible without a 
fundamentally valid model and approach. 
Table 8.  Study 3, Identification: Median Error and IQR in % 
for Measured and Simulated Pressures and Volumes 
Over All 5 Identified Segments 
 
Absolute Percentage Error for Measured and  
Simulated Arterial Pressures and CI 
   MAP 
 (%) 
 MPAP 
 (%) 
 CI 
 (%) 
 median   2.93   1.54   5.00 
 IQR   1.31   8.83   0.73 
MAP = mean arterial pressure, MPAP = mean pulmonary artery 
pressure, CI = cardiac index. 
 
 Table  4 shows the median absolute percentage errors and 
IQR for prediction 1 for study 1. This first prediction used 
the population-specific rule obtained only from the Y 
population to describe the changes in the adrenaline-specific 
model parameters that are caused by an increase in the 
adrenaline dose from 20 ng/min/kg to 160 ng/min/kg. 
Predictions were performed for the O, YM, YF, OM and OF 
groups with absolute percentage errors less than 14% in the 
pressures and less than 8% for the stroke volume. This low 
level of prediction error is a very good result, as bigger 
differences might be expected in the adrenaline dose 
response between the young (Y) and older (O) group, and 
also between male (M) and female (F) groups. Nevertheless, 
reasonably good predictions were obtained, showing the 
general applicability of the CVS model and methods. 
Table  9.  Study 3, Prediction: Absolute Difference in % for 
Measured and Predicted Pressures and CI for 
Predicted Segment  h12 when the Parameter Trends 
for h1 to h6 are Used 
 
Absolute Percentage Error for Measured and  
Predicted Arterial Pressures and CI 
 MAP   MPAP   CI 
 (mmHg)   (mmHg)   ( l / min / m
2 ) 
 6.87   1.06   10.34 
MAP = mean arterial pressure, MPAP = mean pulmonary artery pressure, CI = cardiac 
index. 
 
  More specifically, MAP in the older (O) group was 
consistently under-predicted (median absolute percentage 
error 10%). However this bias is in accordance with the 
results from [15], where MAP decreases more in the Y group 
then it does for the O group. Thus, this trend, when 
calculating the prediction rules from the Y group, is 
transferred to the predictions in the O group. However, these 
prediction errors are still within clinically reasonable or 
 
Fig. (8). Study 3: Clinical mean arterial (MAP), mean pulmonary artery (MPAP) pressure and cardiac index (CI) as obtained from [17] vs 
simulated pressures and CI. Solid lines represent the clinical data and circles represent the CVS model simulation output using identified 
patient-specific parameters.  
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acceptable ranges. This result also shows that same cohorts 
may well require cohort-specific rules, even if the general 
trends are similar. 
 Table  5 shows the median absolute percentage errors and 
IQR for prediction 2 for study 1. This second prediction uses 
the same population-specific rules as used in prediction 1. 
However, in contrast to prediction 1, the previous solution is 
used as initial solution and not the baseline solution. Thus, 
more information is included in the prediction process, 
especially for predictions at the end of the study (for higher 
doses) where it would be expected that the remaining model 
parameters have also changed slightly over the longer time 
scale of the study. Hence, better prediction results are 
obtained with median errors less than 7% for arterial 
pressures and stroke volume. 
  Importantly, these 2 predictions in study 1 show how the 
CVS model might potentially be best used in clinical 
application. First, a baseline solution for the specific patient 
needs to be obtained from regular measurements to create a 
patient-specific model. Next, prediction rules, likely pre-
existing, for the adrenaline-specific parameters can then be 
used to predict the response to a change in the current 
adrenaline dose. This first prediction might well yield a 
reasonable result, and different doses can be tested and 
predicted with the most appropriate dose chosen for the 
patient. 
  However, as time progresses and the dose changes, much 
better predictions can be obtained by using the previous 
model parameter values obtained from a different or prior 
dose. For example, if 60 ng/kg/min at time=2hr, is used as 
initial parameter set for the prediction at 80 ng/kg/min or 
time=3hr, a better result might occur. Additionally, and 
importantly, once changes have been made, prior data can be 
used to create a patient-specific rule or sensitivity to change 
the adrenaline-specific parameters more accurately. This 
latter approach would enable the ability to track patient 
evolution in response, which is a potential clinical datum on 
its own right. 
 Tables  7 and 9 show the absolute percentage errors for 
the predictions performed for studies 2 and 3. The median 
prediction errors are less than 6% and less than 11% for 
studies 2 and 3, respectively. These are good results when 
the very limited data available in these 2 studies is 
considered. In particular, all the minimum and maximum 
arterial pressures and volumes had to be estimated creating a 
substantial level of potential error for a limited result. 
Nevertheless, reasonably good prediction results are 
obtained, illustrating the robustness of the estimations and 
identification process. 
  Comparisons of the adrenaline-specific prediction rules 
between the 3 studies are not fully possible. Study 1 is based 
on a dose change for a short time, where each infusion lasts 
8 minutes, in healthy subjects. In contrast, studies 2 and 3 are 
observational studies in an ICU environment over a much 
longer time period of 14 and 24 hours with different doses in 
between. Hence, the different time scales prevent further 
direct comparison. 
  However, the linear prediction rules for studies 2 and 3 
are, despite the many assumptions that have to be made, 
relatively similar, as seen in Fig. (4). The upper panel shows 
the prediction rule for Eeslvf  for study 2 (solid line) and 3 
(dashed line), the lower panel shows the prediction rule for 
Eesrvf . In particular, it should be noted how the right 
ventricular contractility  Eesrvf  decreases, instead of the 
expected increase. This result could be due to inaccurate 
estimations in the right ventricle volume based on the 
assumptions made and/or due to the underlying cardiac and 
circulatory dysfunctions present in the critically ill patients 
for studies 2 (myocardial dysfunction after CABG) and 3 
(septic shock). This type of inconclusive result is an 
expected limitation of using severely restricted data and 
making compensatory assumptions that may not hold for 
broader cohorts. 
  Obviously, a larger number of studies would help to 
better confirm these initial results. The overall goal remains 
to develop adrenaline-specific parameter rules or 
identification methods that can easily be adjusted to the 
individual patient regarding age, sex, current drug dose and 
underlying disease state. These could then directly be used in 
clinical application and only one baseline solution would be 
necessary to start the process, rather than using a whole set 
of identification results to create a rule, as was done in this 
current study. However, despite these and other limitations, 
this study has demonstrated the potential of this model for 
therapeutic decision support, particularly for cases where 
data density is higher as in study 1. Finally, it should be 
noted that clinically, if data is gathered automatically at the 
bedside by computer, such data density should be readily 
expected and available. 
5. CONCLUSION 
  The integral-based optimization method successively 
identified patient-specific parameters for the minimal cardiac 
model for 3 studies of adrenaline therapies. This study shows 
the ability of the model to adequately and realistically 
capture (with unique values) the impact of pressure-volume 
changes with adrenaline in healthy subjects as well as in 
critically ill patients. 
  Furthermore, the integral-based optimization led to the 
successful definition of adrenaline-specific parameters for 
the CVS model. These adrenaline-specific parameter values 
were used to test the predictive ability of the model. This 
further demonstration shows the ability of the model to 
adequately and realistically simulate the impact of pressure-
volume changes with adrenaline in healthy subjects and 
critically ill patients. Moreover, such rules can be similarly 
derived and used to predict the response towards a variety of 
interventions, while errors or deviations from can point out 
developing disease states or hemodynamic instabilities. This 
research thus increases the confidence in the clinical 
applicability and validity of this model and its use in clinical 
diagnostic monitoring and drug dose guidance. 
6. CARDIOVASCULAR MODEL EQUATIONS 
  Ventricle volumes and flows: 
Vlvf = Vlv Vspt  (1) 
Vrvf = Vrv +Vspt  (2) 162    The Open Medical Informatics Journal, 2010, Volume 4  Chase et al. 
Vpcd = Vlv +Vrv  (3)   
Ppcd = P 0,pcd e
pcd VpcdV0,pcd () 1 ()  (4) 
Pperi = Ppcd + P th  (5) 
 Lav  Qav = P lv  P ao QavRav  (6) 
 
Lmt  Qmt = Ppu  P lv QmtRmt  (7) 
 
Lpv  Qpv = P rv  Ppa QpvRpv  (8) 
 Ltc  Qtc = P vc  P rv QtcRtc  (9) 
 Pressures: 
Ppu = Epu Vpu Vd,pu () + P th  (10) 
Ppa = Epa Vpa Vd,pa () + P th  (11) 
P vc = Evc Vvc Vd,vc () + P th  (12) 
P ao = Eao Vao Vd,ao ()  (13) 
P sys = Esys Vsys Vd,sys ()  (14) 
P cap = Ecap Vcap Vd,cap ()  (15) 
 Volumes: 
 
 Vpv = Qpulout Qmt  (16) 
 
 Vpa = Qpv Qpulin  (17) 
 
 Vvc = Qvr Qtc  (18) 
 
 Vao = Qav Qsys  (19) 
 
 Vsys = Qsys Qvr  (20) 
 
 Vcap = Qpulin Qpulout  (21) 
 Flows: 
Qsys =
P ao  P sys
Rsys
 (22) 
Qvr =
P sys  P vc
Rvr
 (23) 
Qpulin =
Ppa  P cap
Rpulin
 (24) 
Qpulout =
P cap  Ppu
Rpulout
 (25) 
 Ventricular  interaction: 
P lv = P lvf + Pperi  (26) 
P rv = P rvf + Pperi  (27) 
P lvf = drilEes,lvf  Vlvf Vd,lvf ()
+ 1 driL () P 0,lvf  e
lvf Vlvf V0,lvf () 1 ()
 (28) 
P rvf = driREes,rvf  Vrvf Vd,rvf ()
+ 1 driR () P 0,rvf  e
rvf Vrvf V0,rvf () 1 ()
 (29) 
et () Ees,spt  Vspt Vd,spt () + (1 et () )P 0,spt  e
spt VsptV0,spt () 1 () =
et () Ees,lvf  Vlv Vspt () + 1 et () () P 0,lvf  e
lvf VlvVspt () 1 ()
et () Ees,rvf  Vrv +Vspt ()  1 et () () P 0,rvf  e
rvf Vrv+Vspt () 1 ()
 (30) 
ABBREVIATIONS 
  =  Parameter in EDPVR 
P 0   =  Parameter in EDPVR 
lv =  Left  ventricle 
rv =  Right  ventricle 
lvf  =  Left ventricle free wall 
rvf  =  Right ventricle free wall 
spt =  Septum 
pcd =  Pericardium 
V0   =  Volume at zero pressure 
Vd  =  Unstressed  chamber  volume 
R =  Resistance 
E =  Elastance 
L =  Inertance 
P =  Pressure 
Q =  Flow 
V =  Volume 
mt =  Mitral  valve 
tc =  Tricuspid  valve 
av =  Aortic  valve 
pv =  Pulmonary  valve 
pulin = Systemic  pulmonary 
pulout =  Venous  pulmonary 
sys =  Systemic 
cap =  Capillary 
vr =  Venous  return 
es =  End-systolic 
P th =  Intrathoracic  pressure 
period  =  Heart beat period 
driL  =  Activation (driver) function for LV 
driR  =  Activation (driver) function for RV 
driS  =  Activation (driver) function for Septum Model-Based Prediction of the Patient-Specific Response to Adrenaline  The Open Medical Informatics Journal, 2010, Volume 4    163 
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